Rivaroxaban in stable cardiovascular disease

Rivaroxaban in stable cardiovascular disease

A response to "Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease" N Engl J Med 2017; 377:1319-1330.

Bibliographic Details
Main Authors:	Cahill, T, Wijesurendra, R, Casadei, B
Format:	Journal article
Language:	English
Published:	Massachusetts Medical Society 2018

Similar Items

Cost-Effectiveness Analysis of Rivaroxaban in Chinese Patients With Stable Cardiovascular Disease
by: Tianyu Feng, et al.
Published: (2022-06-01)

The Role of Rivaroxaban in the Treatment of Patients with Stable Coronary Artery Disease
by: O. V. Averkov
Published: (2019-10-01)

Rivaroxaban: Expanded Role in Cardiovascular Disease Management—A Literature Review
by: Muhammad Ajmal, et al.
Published: (2021-01-01)

Non-embolic outcomes in patients with cardiovascular disease and atrial fibrillation treated with rivaroxaban
by: Francisco Marin, et al.
Published: (2023-02-01)

Low Dose Rivaroxaban for Atherosclerotic Cardiovascular Diseases: A Systematic Review and Meta-analysis
by: Can Chen, et al.
Published: (2021-02-01)

Seek and ye shall find… subclinical atrial fibrillation in high-risk elderly patients.
by: Wijesurendra, R, et al.
Published: (2017)

Update on Rivaroxaban
by: Osama Moussa, et al.
Published: (2010-01-01)

Rivaroxaban monograph
by: Teerapat Nantsupawat, et al.
Published: (2015-04-01)

Mechanisms of atrial fibrillation
by: Wijesurendra, RS, et al.
Published: (2019)

RIVAROXABAN IN LONG-TERM PREVENTION OF CARDIOVASCULAR EVENTS IN PATIENTS WITH ACUTE CORONARY SYNDROME
by: S. V. Shalaev
Published: (2017-12-01)

Rivaroxaban in atrial fibrillation
by: Giorgi MA, et al.
Published: (2012-08-01)

Impact of rivaroxaban on stent thrombosis and secondary prevention of cardiovascular events in acute coronary syndrome
by: Krohn-Grimberghe M, et al.
Published: (2014-05-01)

The Impact of Combination Therapy with Rivaroxaban and Acetylsalicylic Acid in Patients with Coronary Heart Disease on the Achievement of the Target for Reducing Mortality from Cardiovascular Diseases of the Federal Project "Fight against Cardiovascular Diseases"
by: M. V. Zhuravleva, et al.
Published: (2022-03-01)

Comparison of Aspirin and Rivaroxaban Plus Aspirin in the Management of Stable Coronary Artery Disease or Peripheral Artery Disease: A Systematic Review of Randomized Controlled Trials
by: Debasu Z, et al.
Published: (2022-09-01)

Prospects of rivaroxaban application in treatment of patients with chronic ischemic heart disease
by: N. B. Perepech
Published: (2020-01-01)

Rivaroxaban and Hemostasis in Emergency Care
by: Jürgen Koscielny, et al.
Published: (2014-01-01)

Pharmacogenetics and pharmacokinetics of rivaroxaban in patients with atrial fibrillation and chronic kidney disease
by: N. A. Shatalova, et al.
Published: (2023-11-01)

Clopidogrel combined with rivaroxaban in peripheral artery disease after revascularization
by: Min Lu, et al.
Published: (2025-01-01)

A Case of Rivaroxaban Associated Intracranial Hemorrhage
by: Jean Chin-Yu Lo, et al.
Published: (2014-07-01)

Life-Threatening Hemopericardium Associated with Rivaroxaban
by: Sijan Basnet, et al.
Published: (2017-01-01)

Intravesicular Onabotulinumtoxin A Hemorrhage on Rivaroxaban
by: Allison Eubanks, et al.
Published: (2019-01-01)

Rivaroxaban’s vascular dose for the neurovascular clinician
by: Ji Y. Chong, et al.
Published: (2024-07-01)

Intracranial hemorrhage in patient treated with rivaroxaban
by: Michelle Molina, et al.
Published: (2014-03-01)

Rivaroxaban in atrial fibrillation cardioversion: an update
by: Lavalle C, et al.
Published: (2019-05-01)

Hemomediastino en tomador de rivaroxaban
by: Pablo Ruiz-Sada, et al.
Published: (2016-12-01)

Idiosyncratic Liver Injury due to Rivaroxaban
by: Aneesh Cherakulam Ratheendran, et al.
Published: (2017-12-01)

Rivaroxaban for the treatment of cerebral venous thrombosis
by: Sara Esmaeili, et al.
Published: (2021-02-01)

Effects of ticagrelor on the pharmacokinetics of rivaroxaban in rats
by: Jia Chong, et al.
Published: (2020-01-01)

International longitudinal registry of patients with atrial fibrillation and treated with rivaroxaban: RIVaroxaban Evaluation in Real life setting (RIVER)
by: Jan Beyer-Westendorf, et al.
Published: (2019-04-01)

Comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban in dogs
by: Alex M. Lynch, et al.
Published: (2024-11-01)

Dabigatran and Rivaroxaban Use in Atrial Fibrillation Patients on Hemodialysis
by: Chan, Kevin E., et al.
Published: (2016)

Is a Lower Dose of Rivaroxaban Required for Asians? A Systematic Review of a Population Pharmacokinetics and Pharmacodynamics Analysis of Rivaroxaban
by: Xiao-Qin Liu, et al.
Published: (2023-02-01)

Histopathological and immunological characteristics of tachycardia-induced cardiomyopathy
by: Wijesurendra, R, et al.
Published: (2017)

RIVAROXABAN OF THE BAYER COMPANY SIGNIFICANTLY (BY 24%) REDUCES THE RISK OF STROKE, CARDIOVASCULAR DEATH AND MYOCARDIAL INFARCTION IN PATIENTS WITH CHRONIC ISCHEMIC HEART DISEASE OR PERIPHERAL ARTERIAL DISEASE
by: статья Редакционная
Published: (2017-11-01)

RIVAROXABAN OF THE BAYER COMPANY SIGNIFICANTLY (BY 24%) REDUCES THE RISK OF STROKE, CARDIOVASCULAR DEATH AND MYOCARDIAL INFARCTION IN PATIENTS WITH CHRONIC ISCHEMIC HEART DISEASE OR PERIPHERAL ARTERIAL DISEASE
by: статья Редакционная
Published: (2017-11-01)

Successful Treatment and Secondary Prevention of Venous Thrombosis Secondary to Behçet Disease with Rivaroxaban
by: Ana Boban, et al.
Published: (2016-01-01)

The Anticoagulation in Patients with Atrial Fibrillation: Rivaroxaban and Warfarin
by: I. Yu. Koroleva, et al.
Published: (2016-11-01)

Effects of rivaroxaban and apixaban on intimal hyperplasia in rabbits
by: Mustafa Baris Kemahli, et al.
Published: (2022-03-01)

Effects of Carbamazepine and Phenytoin on Pharmacokinetics and Pharmacodynamics of Rivaroxaban
by: Lien Thi Ngo, et al.
Published: (2020-10-01)

Fatigue after initiating rivaroxaban for venous thromboembolism
by: Tina Margrethe Karlsvik, et al.
Published: (2020-05-01)